Published Cost-Effectiveness Studies on GLP-1s: What ICER Actually Concluded

The Institute for Clinical and Economic Review (ICER) has issued formal cost-effectiveness assessments of GLP-1 medications used for weight management. Their conclusions matter because payers reference ICER work in coverage decisions. Here's what ICER actually said.

What ICER Does

ICER conducts independent cost-effectiveness analyses of medical interventions in the United States. They use quality-adjusted life year (QALY) frameworks and specific willingness-to-pay thresholds ($100,000-$150,000 per QALY is a common range) to determine whether a medication's clinical benefit justifies its price.

ICER doesn't set coverage policy directly. But their reports influence how payers evaluate whether medications are priced within reasonable range of their clinical value, which in turn affects formulary decisions and negotiated pricing.

The GLP-1 Weight Management Assessment

ICER's evaluation of GLP-1s for weight management concluded, generally, that these medications provide meaningful clinical benefit but at prices that exceed standard cost-effectiveness thresholds by wide margins at U.S. list prices. The reports specified value-based price benchmarks materially below list prices — for both Wegovy and Zepbound — that would be needed to reach conventional cost-effectiveness thresholds.

The gap between actual price and value-based benchmark has been substantial. This is part of the pricing pressure that manufacturers responded to with expanded cash-pay programs (NovoCare, LillyDirect) that offer discounted rates outside insurance channels.

What ICER Didn't Conclude

ICER didn't conclude that GLP-1s shouldn't be covered. Their frameworks specify cost-effective price ranges, not go/no-go recommendations. Coverage decisions incorporate additional factors — patient equity, budget impact, treatment landscape — that go beyond narrow cost-effectiveness analysis.

Their assessments also don't address longer-term cost offsets from CV, kidney, or metabolic outcome improvements. If a GLP-1 prevents a heart attack or kidney failure, downstream cost savings partially offset the medication's price. Full offset accounting was outside the scope of the initial assessments but has been incorporated in more recent updates.

How Payers Have Used the Reports

Some payers cite ICER work in negotiations with manufacturers, using value-based benchmarks as anchor points for pricing discussions. Some cite the reports in prior authorization criteria — requiring documented BMI thresholds, comorbidity presence, or step therapy before covering GLP-1s.

Public sector payers (Medicare, Medicaid) have been more explicit about weighing cost-effectiveness in coverage decisions. Private payers have varied in how directly they cite ICER work versus incorporating it into internal actuarial analysis.

The Bigger Value Question

Whether GLP-1s are "worth the price" depends on framing. To an individual patient, the calculation includes personal weight loss, quality of life change, and out-of-pocket cost — a different calculation than payer-side QALY math. Both framings are legitimate; they produce different conclusions. Understanding what ICER analyzes and what it doesn't helps patients interpret both the reports themselves and the coverage decisions that reference them.

Where to Start